KRW 12270.0
(-2.54%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -28.79 Billion KRW | -369.55% |
2022 | 10.68 Billion KRW | 224.25% |
2021 | 3.29 Billion KRW | -87.78% |
2020 | 26.95 Billion KRW | -22.82% |
2019 | 34.92 Billion KRW | 337.18% |
2018 | 7.98 Billion KRW | 64.11% |
2017 | 4.86 Billion KRW | 175.43% |
2016 | -6.45 Billion KRW | -282.54% |
2015 | -1.68 Billion KRW | -214.52% |
2014 | 1.47 Billion KRW | -88.03% |
2013 | 12.3 Billion KRW | 113.4% |
2012 | 5.76 Billion KRW | -65.2% |
2011 | 16.57 Billion KRW | -19.27% |
2010 | 20.53 Billion KRW | 14.02% |
2009 | 18 Billion KRW | 163.77% |
2008 | 6.82 Billion KRW | -64.4% |
2007 | 19.17 Billion KRW | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q3 | -3.31 Billion KRW | 74.28% |
2024 Q1 | -2.25 Billion KRW | 85.28% |
2024 Q2 | -12.88 Billion KRW | -472.22% |
2023 Q2 | -6.08 Billion KRW | -38.36% |
2023 Q1 | -4.39 Billion KRW | -155.65% |
2023 FY | -28.79 Billion KRW | -369.55% |
2023 Q3 | -3.07 Billion KRW | 49.5% |
2023 Q4 | -15.29 Billion KRW | -397.88% |
2022 Q3 | 3.99 Billion KRW | 354.13% |
2022 Q2 | -1.57 Billion KRW | -557.59% |
2022 FY | 10.68 Billion KRW | 224.25% |
2022 Q4 | 7.9 Billion KRW | 97.7% |
2022 Q1 | 343.66 Million KRW | -38.39% |
2021 Q3 | -2.14 Billion KRW | -171.95% |
2021 Q1 | 1.9 Billion KRW | -84.49% |
2021 Q2 | 2.97 Billion KRW | 56.33% |
2021 Q4 | 557.8 Million KRW | 126.06% |
2021 FY | 3.29 Billion KRW | -87.78% |
2020 FY | 26.95 Billion KRW | -22.82% |
2020 Q1 | -693.35 Million KRW | -104.14% |
2020 Q2 | 1.07 Billion KRW | 254.75% |
2020 Q4 | 12.26 Billion KRW | -14.33% |
2020 Q3 | 14.31 Billion KRW | 1234.27% |
2019 Q1 | 6.72 Billion KRW | 463.63% |
2019 Q3 | 16.88 Billion KRW | 411.98% |
2019 Q4 | 16.73 Billion KRW | -0.9% |
2019 FY | 34.92 Billion KRW | 337.18% |
2019 Q2 | -5.41 Billion KRW | -180.44% |
2018 Q2 | 100.37 Million KRW | -98.11% |
2018 Q4 | -1.85 Billion KRW | -141.75% |
2018 FY | 7.98 Billion KRW | 64.11% |
2018 Q1 | 5.3 Billion KRW | -13.27% |
2018 Q3 | 4.43 Billion KRW | 4314.56% |
2017 Q4 | 6.11 Billion KRW | 37.21% |
2017 FY | 4.86 Billion KRW | 175.43% |
2017 Q3 | 4.46 Billion KRW | 265.44% |
2017 Q2 | -2.69 Billion KRW | 10.6% |
2017 Q1 | -3.01 Billion KRW | -105.81% |
2016 Q4 | -1.46 Billion KRW | 19.25% |
2016 Q1 | 277.6 Million KRW | -95.87% |
2016 FY | -6.45 Billion KRW | -282.54% |
2016 Q2 | -3.45 Billion KRW | -1343.53% |
2016 Q3 | -1.81 Billion KRW | 47.44% |
2015 Q3 | -2.22 Billion KRW | 5.82% |
2015 Q1 | -3.81 Billion KRW | 0.0% |
2015 FY | -1.68 Billion KRW | -214.52% |
2015 Q2 | -2.36 Billion KRW | 38.09% |
2015 Q4 | 6.71 Billion KRW | 401.86% |
2014 FY | 1.47 Billion KRW | -88.03% |
2014 Q3 | -1.18 Billion KRW | -34.75% |
2014 Q2 | -881.68 Million KRW | -118.46% |
2014 Q4 | - KRW | 100.0% |
2014 Q1 | 4.77 Billion KRW | -59.96% |
2013 Q1 | 348.88 Million KRW | -23.01% |
2013 FY | 12.3 Billion KRW | 113.4% |
2013 Q2 | -360.11 Million KRW | -203.22% |
2013 Q3 | 394.46 Million KRW | 209.54% |
2013 Q4 | 11.92 Billion KRW | 2923.42% |
2012 Q4 | 453.15 Million KRW | -79.97% |
2012 Q1 | 2.76 Billion KRW | 0.0% |
2012 Q2 | 287.82 Million KRW | -89.59% |
2012 Q3 | 2.26 Billion KRW | 685.9% |
2012 FY | 5.76 Billion KRW | -65.2% |
2011 FY | 16.57 Billion KRW | -19.27% |
2011 Q4 | - KRW | -100.0% |
2011 Q3 | 3.37 Billion KRW | -34.16% |
2011 Q2 | 5.12 Billion KRW | -5.86% |
2011 Q1 | 5.44 Billion KRW | 55.5% |
2010 Q1 | 5.8 Billion KRW | -13.94% |
2010 FY | 20.53 Billion KRW | 14.02% |
2010 Q2 | 5.37 Billion KRW | -7.37% |
2010 Q3 | 5.84 Billion KRW | 8.76% |
2010 Q4 | 3.5 Billion KRW | -40.11% |
2009 Q1 | 2.33 Billion KRW | 268.12% |
2009 Q3 | 4.35 Billion KRW | -4.86% |
2009 Q2 | 4.57 Billion KRW | 95.99% |
2009 Q4 | 6.74 Billion KRW | 54.95% |
2009 FY | 18 Billion KRW | 163.77% |
2008 Q2 | 3.32 Billion KRW | 61.34% |
2008 Q3 | 2.82 Billion KRW | -15.1% |
2008 Q4 | -1.38 Billion KRW | -149.15% |
2008 FY | 6.82 Billion KRW | -64.4% |
2008 Q1 | 2.06 Billion KRW | -64.39% |
2007 Q4 | 5.79 Billion KRW | 21.78% |
2007 Q3 | 4.75 Billion KRW | 7.77% |
2007 Q2 | 4.41 Billion KRW | 4.7% |
2007 Q1 | 4.21 Billion KRW | 0.0% |
2007 FY | 19.17 Billion KRW | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Yuyu Pharma, Inc. | -7.18 Billion KRW | -301.028% |
Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 149.66% |
Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 51.671% |
Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -242.208% |
Yuhan Corporation | 93.5 Billion KRW | 130.796% |
Dong-A ST Co., Ltd. | 11.12 Billion KRW | 358.912% |
SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -16.062% |
Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 119.693% |
Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 920.766% |
Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -1048.95% |
Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -1288.558% |
MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -536.431% |
Hana Pharm Co., Ltd. | 22.33 Billion KRW | 228.947% |
Yuyu Pharma, Inc. | -7.18 Billion KRW | -301.028% |
Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -37.518% |
REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 903.641% |
Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 75.651% |
JW Holdings Corporation | 19.02 Billion KRW | 251.356% |
Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 63.514% |
Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 113.55% |
JW Pharmaceutical Corporation | 37 Billion KRW | 177.818% |
Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 49.765% |
Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 570.411% |
Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1831.095% |
Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 675.403% |
Yuyu Pharma, Inc. | -7.18 Billion KRW | -301.028% |
Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 177.903% |
Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 125.827% |
JW Pharmaceutical Corporation | 37 Billion KRW | 177.818% |
Yuhan Corporation | 93.5 Billion KRW | 130.796% |
Jeil Pharma Holdings Inc | -16.24 Billion KRW | -77.218% |
Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -643.056% |
Suheung Co., Ltd. | 6.11 Billion KRW | 570.606% |
JW Pharmaceutical Corporation | 37 Billion KRW | 177.818% |
Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 252.321% |
Korea United Pharm Inc. | 48.26 Billion KRW | 159.669% |
CKD Bio Corp. | -24.19 Billion KRW | -19.035% |
Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 220.406% |
Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 204.954% |
Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 196.719% |
Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 49.765% |
Chong Kun Dang Holdings Corp. | 47 Billion KRW | 161.261% |
Boryung Corporation | 40.2 Billion KRW | 171.63% |
Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 8.082% |
Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -1048.95% |
JW Lifescience Corporation | 28.14 Billion KRW | 202.322% |